Blogs

SBW/Toxis takes part in three different TEKES-projects (TEKES – the Finnish Funding Agency for Technology and Innovation) with academic grous as well as other companies. Our participation in R&D projects is always aimed at gaining new expertise, methods and models for our customers.

SBW/Toxis has published a research article in assessing the methods for blood sampling from laboratory animals, aiming at the least stressful method for obtaining better pharmacokinetic and pharmacodynamics data. This study supports the Toxis ethics – animal wellbeing is an intrinsic part of our daily practice. It is important to use the optimal method for repeated blood sampling to ensure minimal stress to mice, and also to provide better pharmacokinetic and pharmacodynamic data.

Three long-term phase III oncology studies analysed by SBW/4Pharma were published recently: FinXX study, Finher study and GAD study

In FinXX study 1500 women with early breast cancer were followed up for a median time of 3 years before the present interim analysis. The analysis showed that integration of capecitabine into anthracycline-/taxane-based adjuvant therapy had significantly better efficacy compared with schedule of standard agents. The rate of breast cancer recurrence was reduced by 34% with a manageable toxicity profile.

We are again participating in the Bio International Convention. This year the event takes place in May 3-6, 2010 McCormick Place Chicago, IL.

Please contact us by email (info@sbw.fi), phone (+358 10 439 9440) or BIO partnering system to learn how our comprehensive and cost efficient service platform and business models ranging from fee for service/FTE to joint discovery programs can help you in Discovering Success.

We are recruiting business development persons to our office in Pune India. Please see the careers page for more information.